[A prospective study of nylestriol on plasma lipids in postmenopausal women].
A prospective, double-blind clinical study has been carried out in 90 chinese women with postmenopausal period covering 0.5 to 21 years by administering a synthetic long-acting estriol derivative-nylestriol in the regimen of 2 mg every 2 weeks for 1 year (49 treated and 41 placebo). The result were: Total cholesterol (TC) and triglyceride (TG) remained unchangeable (P greater than 0.05), while high-density-lipoprotein cholesterol (HDL-C) increased after 6 months, low-density lipoprotein cholesterol (LDL-C) and TC/HDL-C,LDL-C/HDL-C ratios decreased after 3 months of medication (P less than 0.05); FSH were restrained (P less than 0.05), but LH did not change significantly (P greater than 0.05). One third of the women with intact uterus had spotting withdraw bleeding and another one third had moderate amount after the addition of medroxyprogesterone acetate 6 mg daily for 7 days at the end of the 12 months treatment. Side effects included breakthrough bleeding (10.3%), breast tenderness (11.8%), leukorrhagia (29.4). None showed abnormal liver function (GPT).
Cheng
G J
GJ
General Hospital of PLA, Beijing.
D000368:Aged; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D045166:Estradiol Congeners / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000517:prevention & control; D008593:Menopause; D008875:Middle Aged; D011446:Prospective Studies; D011800:Quinestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D045166:Estradiol Congeners; D011800:Quinestrol